Details of the Drug

General Information of Drug (ID: DMPBR0D)

Drug Name
IPH-2102
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [1]
Cross-matching ID
TTD ID
D00RYU

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MHC class I NK cell receptor 2DL1 (CD158A) TT4UXPE KI2L1_HUMAN Antagonist [2]
MHC class I NK cell receptor 2DL2 (CD158b1) TTU0P73 KI2L2_HUMAN Antagonist [2]
MHC class I NK cell receptor 2DL3 (CD158b2) TTEX3SI KI2L3_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
MHC class I NK cell receptor 2DL2 (CD158b1) DTT KIR2DL2 1.69E-05 -0.93 -3.58
MHC class I NK cell receptor 2DL3 (CD158b2) DTT KIR2DL3 5.34E-04 -0.32 -2.19
MHC class I NK cell receptor 2DL1 (CD158A) DTT KIR2DL1 2.29E-06 -0.43 -4.42
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health.
2 Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.